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Interleukin-5 (IL-5) is one of the major regulators of
eosinophilic granulocytes in vivo. IL-5 exerts its pleio-
tropic effects by binding to the IL-5 receptor, which is
composed of an IL-5-specific a chain and a common bc
chain shared with the receptors for IL-3 and granulo-
cyte-macrophage colony-stimulating factor. Previous
studies have shown that binding of IL-5 to its receptor
triggers the activation of multiple signaling cascades,
including the Ras/mitogen-activated protein kinase, the
phosphatidyl -3*-kinase, and the Janus kinase/signal
transducer and activator of transcription pathways.
Here we describe that IL-5 activates the serine/threo-
nine protein kinase Jun N-terminal kinase/stress-acti-
vated protein kinase (JNK/SAPK) pathway. We show
that IL-5 activates TPA response element (TRE)-depend-
ent transcription in transfection experiments. TRE ac-
tivation by IL-5 is mediated by a region of the bc (577–
581) that is also responsible for activation of JNK/SAPK
and for activation of dyad symmetry element (DSE)-de-
pendent transcription. Dominant-negative SAPK or
ERK kinase-1 was used to demonstrate that JNK/SAPK
activation is necessary for induction of DSE- and TRE-
dependent transcription by IL-5, whereas extracellular
signal-regulated kinase 2 was not essential for TRE- and
DSE-dependent transcription. By contrast, IL-5-induced
activation of the tyrosine kinase Janus kinase 2 seems to
be a prerequisite for TRE- and DSE-dependent tran-
scription. Taken together, we show for the first time
that IL-5 activates kinases of the JNK/SAPK family, and
that this activation is linked to IL-5-induced TRE- and
DSE-dependent transcription.
Cytokines such as interleukin (IL)1-3, IL-5, and granulocyte-
macrophage colony-stimulating factor (GM-CSF) play an im-
portant role in hematopoiesis (1–3). IL-3 and GM-CSF are
broad specificity cytokines that have effects on multiple hema-
topoietic cell lineages (3, 4). By contrast, the actions of human
IL-5 are restricted to the eosinophil and basophil lineages,
because a functional IL-5 receptor (IL-5-R) is only expressed on
these cell types (5, 6). IL-5 is essential for eosinophil differen-
tiation (7, 8) and plays an important role in the functioning of
mature eosinophils and basophils (9–13). The IL-5-R is a mul-
timeric molecule composed of a unique a chain associated with
a common bc chain, which is part of the receptors for IL-3 and
GM-CSF (14). Because the bc chain is thought to play a major
role in postreceptor signal transduction, it is not surprising
that IL-3, IL-5, and GM-CSF exert multiple overlapping effects
on cells that have all three receptor complexes (15).
Binding of IL-3, IL-5, or GM-CSF to their receptors leads to
activation of multiple signal transduction pathways. Within
seconds to minutes, multiple cellular proteins become phospho-
rylated on tyrosine residues, an event essential for most bio-
logical functions of these cytokines (12, 16). Because the a and
bc chains of these receptors do not contain any enzymatic
activity, cytoplasmic protein tyrosine kinases are likely to me-
diate this process. We and others have shown that IL-5 binding
leads to rapid and transient activation of the Janus kinase
JAK2 (17–19), one of the kinases involved in activation of STAT
(signal transducer and activator of transcription) proteins (re-
viewed in Ref. 20). In addition, kinases such as Lyn, Syk, fyn,
hck, and BTK are also activated by cytokines of this family
(21–23). Activation of these signaling pathways is mediated by
different functional domains in the bc chain. A membrane-
proximal region containing box1, a motif found in multiple
cytokine receptors, is necessary for JAK2 and STAT3 activa-
tion, induction of c-myc gene expression and cytokine-induced
proliferation (23–27). A more distal region between amino acids
542 and 589 was shown to be involved in activation of the
RAS/MAPK pathway mediated by Shc binding to the bc chain
and for induction of transcription of the immediate-early genes
c-jun and c-fos (24, 25, 28, 29) Moreover, this region was also
implicated in activation of phosphatidylinositol 39-kinase and
p70S6 kinase by GM-CSF (25). Phosphorylation of tyrosine 577
of the bc chain, possibly by JAK2, was shown to be at least
partially responsible for activation of MAPK and c-fos, al-
though also other tyrosine residues are likely to play an impor-
tant role (28, 29). In addition, the proline-rich region of the a
chain was also shown to be involved in activation of different
pathways, such as the JAK2/STAT pathway and cytokine-in-
duced proliferation (27, 30, 31).
Immediate-early gene expression in response to a wide array
of different extracellular stimuli is regulated by a limited
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amount of cis-acting response elements in the promoters of the
induced genes. Among these, the TPA-response element (TRE)
binds transcription factors of the Jun/AP-1 family (reviewed in
Refs. 32 and 33). This element mediates transcriptional acti-
vation by stimuli such as phorbol esters, UV light, tumor ne-
crosis factor a (TNFa), IL-2, and stress induced by heat shock
or protein synthesis inhibitors (33). Jun/AP-1 transcription
factors are homo- or heterodimeric proteins that are activated
by serine and threonine phosphorylation. The kinases that are
responsible for these phosphorylations were described recently
as a novel family of mitogen-activated protein kinases
(MAPKs), the Jun N-terminal kinases (JNKs, also known as
stress-activated protein kinases (SAPKs); reviewed in Refs.
34–36). The JNK/SAPKs themselves are activated by dual
phosphorylation at conserved threonine and tyrosine residues,
after which they phosphorylate AP-1 members such as c-Jun
and ATF2 and stimulate their transcriptional activity (34–36).
Another cis-acting element frequently found in promoters of
immediate-early genes is the dyad symmetry element (DSE) or
serum response element (SRE), which was first identified in
the promoter of the c-fos proto-oncogene (reviewed in Ref. 37).
The DSE/SRE binds multiple transcription factors, including
the serum response factor and the ternary complex factor
(TCF) ELK-1 (37, 38). Mitogenic stimulation leads to a rapid
phosphorylation of both serum response factor and TCF/
ELK-1, leading to enhanced DNA binding by serum response
factor and, more importantly, enhanced transcriptional activa-
tion by TCF/ELK-1 (37, 38). In contrast to phosphorylation of
Jun proteins, phosphorylation of TCF/ELK-1 is likely to be
mediated by the classical MAPKs ERK1 and ERK2 (38–40),
although in was more recently shown that the SRE can also be
activated in response to JNK/SAPKs (41, 42).
In this report, we have investigated the effects of IL-5 on
TRE- and DSE-mediated transcription. Here we show that IL-5
efficiently activates TRE- and DSE-containing promoters. We
present evidence that this is likely to be mediated by activation
of JNK/SAPKs. Moreover, we identify the regions in the IL-5-R
a and bc chains responsible for these effects. Finally, we sug-
gest that activation of JAK2 by IL-5 precedes and is necessary
for activation of JNK/SAPKs and TRE- and DSE-dependent
transcription.
MATERIALS AND METHODS
Cell Culture, Reagents, and Antibodies—Rat-1, P19EC, and COS-1
cells were cultured in Dulbecco’s modified Eagle’s medium (Life Tech-
nologies, Inc.) supplemented with 8% heat-inactivated fetal calf serum.
Human TF-1 and mouse BaF3 cells were cultured in RPMI 1640 (Life
Technologies, Inc.) supplemented with 10% heat-inactivated fetal clone
I serum (Hyclone), 50 mm b-mercapthoethanol, and human IL-5 (20 pM
for TF1) or mouse IL-3 (0.1 nM for BaF3). Human IL-5 (hIL-5) was a
kind gift of Dr. D. Fattah (Glaxo Wellcome, Stevenage, United
Kingdom), whereas mouse IL-3 was produced in COS cells by transfect-
ing an expression vector containing the murine IL-3 cDNA. The 12Ca5
antibody to the HA-tag was a generous gift from Marc van Dijk. The
anti-JNK/SAPK antibody (SC-572) was purchased from Santa Cruz
Biotechnology, Inc., and the anti-Jun antibody (Ab-1) was obtained
from Oncogene Science. The MEK inhibitor PD098059 (43) was a gen-
erous gift from David Dudley and Alan Saltiel. The JAK2 inhibitor
AG490 (44) was a generous gift from Alexander Levitzki.
Plasmid Construction—pSGhIL-5Ra was constructed by inserting
the cDNA for the human IL-5a receptor into the NotI/KpnI sites of
pSG513, whereas pSGhIL-5Rb was constructed by inserting the cDNA
for the human bc subunit into the EcoRI sites of pSG513 as described
previously (27). The expression vectors encoding bc mutants 763, 627,
542, 517, 456, dI/II, and dII and a mutants 405, 390, and 366 are
described elsewhere (27). Other bc mutants were generated by progres-
sive deletions using bc 763 and the erase-a-base kit (Promega Corp.).
Stop codons were introduced by ligating in an oligonucleotide contain-
ing stop codons in all reading frames, and the identity of the different
mutants was verified by dideoxy-sequencing using T7 polymerase
(Pharmacia). 3xTREtkCAT, 3xDSEtkCAT (45), and the p54SAPK/JNK
expression vector (46) are described elsewhere. Dominant-negative
SEK (SEK-AL, serine 254 to alanine and threonine 258 to leucine; Refs.
46 and 47) and HA-tagged ERK2 (48) were described previously.
3xTREtataCAT contains three copies of the collagenase TRE coupled to
a synthetic minimal promoter.
Transient Transfections—For transfection experiments, COS-1 cells
were subcultured in six-well dishes (Costar), and 3 h later, the cells
were transfected with 10–20 mg of supercoiled plasmid DNA as de-
scribed previously (27, 49). Rat-1 and P19EC cells were transfected 16 h
after splitting. Following 16–20 h exposure to the calcium-phosphate
precipitate, medium was refreshed, and cells were incubated for 16 h
with IL-5 (0.5 pM). Rat-1 cells were incubated in medium containing
0.5% fetal calf serum 8 h prior to the addition of IL-5. Transfected cells
were subsequently harvested for CAT assays or Immuno-kinase assays.
CAT assays were performed as follows. Cells were lyzed by repeated
freeze-thawing in 250 mM Tris, pH 7.4, 25 mM EDTA. Twenty-five mg of
cellular extract were then incubated in a total volume of 100 ml con-
taining 250 mM Tris, pH 7.4, 2% glycerol, 0.3 mM butyryl coenzyme A,
and 0.05 mCi of [14C]chloramphenicol for 2 h at 37 °C. Reaction products
were then extracted using 400 ml of xylene:pristane (1:2), and the
percentage of acetylated products was then determined using liquid
scintillation counting.
Gel Retardation Assay—Nuclear extracts were prepared from un-
stimulated and IL-5-stimulated cells following a procedure described
previously (27, 49). Oligonucleotides were labeled by filling in the co-
hesive ends with [a-32P]dCTP using Klenow fragment of DNA polym-
erase I. Gel retardation assays were carried out according to published
procedures with slight modifications. Briefly, nuclear extracts (10 mg)
were incubated in a final volume of 20 ml, containing 10 mM HEPES, pH
7.8, 50 mM KCl, 1 mM EDTA, 5 mM MgCl2, 10% (v/v) glycerol, 5 mM
dithiothreitol, 2 mg poly(dI-dC) (Pharmacia Biotech Inc.), 20 mg of
bovine serum albumin, and 1.0 ng of 32P-labeled collagenase TRE oli-
gonucleotide for 20 min at room temperature. Complexes were then
separated though nondenaturing 5% polyacrylamide gels and visual-
ized by autoradiography.
Immunoprecipitation and Immune-Kinase Assays—For metabolic la-
beling experiments, cells were incubated for 3 h in phosphate-free
medium containing 1 mCi/ml [32P]orthophosphate. Cells were then
stimulated with cytokines, and subsequently the cells were lyzed in
RIPA buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.1%
SDS, 0.5% sodium deoxycholate, 5 mM EDTA, 1 mM Na3VO4, 10 mg/ml
aprotinin, 1 mM phenylmethylsulfonyl fluoride, and 1 mM leupeptin) for
15 min on ice. The lysate was centrifuged to remove DNA and cellular
debris. The cell lysates were incubated with the anti-Jun polyclonal
antibody for 2 h at 4 °C. Immune complexes were then precipitated with
protein A-Sepharose for 309 at 4 °C, washed five times with lysis buffer,
and boiled in 1 3 Laemmli’s sample buffer. The proteins were separated
on a 10% polyacrylamide gel. After electrophoresis, the gel was fixed
(50% methanol, 10% acetic acid), dried, and exposed to X-ray films
(Kodak) or analyzed using a phosphorimager (Applied Biosystems).
For immune-kinase assays, cells were lyzed in JNK/SAPK lysis
buffer (20 mM Tris, pH 7.4, 10% glycerol, 1% TX-100, 2 mM EDTA, 2 mM
EGTA, 50 mM b-glycerophosphate, 1 mM Na3VO4, 10 mg/ml aprotinin,
1 mM phenylmethylsulfonyl fluoride, 1 mM leupeptin, and 1 mM benza-
midine), and JNK/SAPK protein was precipitated using the 12Ca5
antibody (for transfected cells) or the JNK/SAPK polyclonal antibody
(SC-572 for endogenous JNK/SAPK) and protein A-Sepharose beads.
After extensive washing with lysis buffer, the beads were resuspended
in 20 ml of kinase buffer (25 mM Hepes, pH 7.5, 20 mM MgCl2, 20 mM
b-glycerophosphate, and 2 mM dithiothreitol) containing 10 mg of GST-
Jun and 10 mCi of [g-32P]ATP. The kinase reaction was performed for 20
min at 30 °C, after which the reaction was terminated by adding 1 3
Laemmli’s sample buffer. Proteins were then separated on 12% poly-
acrylamide gels, after which the gels were fixed, dried, and exposed to
x-ray film. ERK2 immune-kinase assays were performed as described
previously (48).
RESULTS
IL-5 Activates TRE-dependent Transcription—IL-5, the ma-
jor cytokine involved in regulating eosinophil functions, was
demonstrated previously to be able to activate different signal-
ing pathways, including the RAS/MAPK pathway (50), the
phosphatidylinositol 39-kinase pathway (51), and the JAK/
STAT pathway (17–19, 27). Activation of the Jun family of
transcription factors by IL-5, however, was not studied before.
We, therefore, set out to determine whether IL-5 was able to
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activate transcription of reporter constructs containing a TRE,
the natural Jun binding site from the collagenase promoter
(32). For this purpose, we transfected Rat-1 cells with the IL-5
R a and bc chains and different CAT reporter constructs. IL-5
was able to increase CAT activity in cells transfected with a
reporter containing three copies of the TRE linked to the tk
promoter (TREtkCAT) but failed to activate this reporter with-
out TRE sites (Fig. 1A). This effect was not restricted to the tk
promoter, because IL-5 also activated a CAT construct contain-
ing three TREs coupled to a synthetic minimal tata box
(TRETATACAT) but not the enhancerless TATACAT reporter
(Fig. 1A). Similar results were obtained in P19 EC and COS-1
cells (data not shown). These results strongly suggest that IL-5
can activate TRE-dependent transcription in these cell types.
Previously, it was shown that activation of different signal-
ing pathways can be assigned to different domains of the bc
chain of the IL-5 and GM-CSF receptors (24–28). We, there-
fore, tested a previously described set of carboxyl-terminal
deletions of the bc chain for IL-5-dependent activation of the
TRETATACAT reporter. Deletion of the most carboxyl-termi-
nal 254 amino acids (627) did not alter the effect of IL-5 on
TRE-dependent CAT activity (Fig. 1B). However, further dele-
tion of 85 amino acids (542) resulted in a complete loss of
IL-5-induced TREtataCAT activity. This region (542–627) was
described previously to be involved in activation of the RAS/
MAP kinase pathway by GM-CSF (28). To be able to localize
the residues of the bc chain involved in TRE activation more
precisely, we generated a new set of bc chain mutants using S1
nuclease. As shown in Fig. 1C, deletion down to amino acid 581
did not significantly decrease IL-5-induced TREtataCAT activ-
ity. Interestingly, further deletion of 4 amino acids (577) re-
sulted in a complete loss of IL-5-induced TRE activity (Fig. 1C),
which was also observed in P19 EC cells (data not shown). The
expression of all mutants was verified by Western blotting
using a rabbit anti-bc antibody (data not shown). Therefore, the
region of the bc chain around tyrosine 577 is likely to be
involved in activation of TRE-dependent transcription upon
IL-5 stimulation.
It was suggested previously that the bc chain of the IL-5-R is
the major player in IL-5-induced signal transduction. We and
others have, however, shown that the cytoplasmic region of the
a chain is necessary for IL-5-induced JAK2 and STAT3 activity
(27, 30, 31). To determine whether the a chain plays a role in
IL-5-induced TRE activity, we transfected different carboxyl-
terminal deletions of the a chain together with the wild-type bc
chain and the TREtataCAT reporter into Rat-1 cells. As we
have described for IL-5-induced STAT3 activity (27), the region
between amino acids 366 and 390 of the a chain is also neces-
sary for IL-5-induced TREtataCAT activity (Fig. 1D). Impor-
tantly, a366 was shown previously to be able to form a high
affinity complex with the bc chain (30), showing that the failure
of this mutant to activate TRE-dependent transcription is not
trivial. Taken together, activation of TRE-dependent transcrip-
tion by IL-5 is mediated by a region containing tyrosine 577 of
the bc chain and the proline-rich region 366–390 of the a chain.
IL-5 Induces Hyperphosphorylation of c-Jun and Activation
of JNK/SAPK—The activity of transcription factor Jun/AP-1
can be regulated at the DNA-binding level or the transcription
activation level (reviewed in Refs. 32 and 33). To discriminate
between these two possibilities, we examined Jun/AP-1 DNA
binding activity in TF-1 cells stimulated with IL-5 or IL-3. For
this purpose, we isolated nuclear extracts from these cells and
assayed them for binding to the collagenase TRE in a band shift
assay. As shown in Fig. 2A, neither IL-5 nor IL-3 significantly
altered Jun/AP-1 binding activity in TF-1 cells or BaF3 cells
stably transfected with the IL-5 receptor (data not shown).
Therefore, it seemed likely that the observed activation of
TRE-dependent transcription was caused by an IL-5-induced
increase in the transcriptional activation potential of c-Jun. As
was reported previously, phosphorylation of two residues near
the amino terminus of c-Jun by kinases of the JNK/SAPK
family are thought to regulate transcriptional activation by
c-Jun (33). We thus set out to determine whether IL-5 treat-
ment altered the phosphorylation status of c-Jun. Orthophos-
phate-labeled TF-1 cells were treated with IL-5 or the potent
JNK/SAPK activators TNFa and cycloheximide, after which
Jun phosphorylation was studied by immunoprecipitation. As
was expected, we observed a dose-dependent increase in Jun
phosphorylation by IL-5, albeit at lower levels than Jun phos-
phorylation obtained after TNFa or cycloheximide stimulation
(Fig. 2B, CH).
To determine whether the observed increase in Jun phospho-
rylation upon IL-5 stimulation was caused by an increase in
JNK/SAPK kinase activity, we performed an immune-complex
kinase assay on IL-5-stimulated TF-1 cells. JNK/SAPK was
precipitated from TF-1 lysates using a polyclonal antibody
against JNK2 (recognizing JNK1, JNK2, and p54b), and JNK/
SAPK activity was determined using purified GST-Jun fusion
protein as a substrate. As shown in Fig. 2C, IL-5 treatment
indeed caused a 3-fold enhancement in JNK/SAPK kinase ac-
tivity, which again was lower than the activation obtained with
cycloheximide (CH). To investigate a similar enhancement in
JNK/SAPK kinase activity that was present in the cells that
were used for assaying TRE activation, we transiently trans-
fected an epitope-tagged version of p54SAPK/JNK together
with the IL-5-R into Rat-1 and COS-1 cells. The activity of the
FIG. 1. Activation of TRE-dependent transcription by IL-5. A,
Rat-1 cells were transfected with expression vectors encoding the IL-5
receptor a and bc chains and tk- or tata-CAT reporters with or without
three copies of the collagenase TRE. Twenty-four h after transfection,
cells were stimulated with IL-5 (0.5 nM) for 12 h, after which the cells
were harvested, and CAT activity was determined. IL-5 treatment
enhances CAT activity in cells expressing both TRE-containing report-
ers but not in the control cells. B, Rat 1 cells were transfected as
described in A with the TREtataCAT reporter, the IL-5-R a plasmid,
and different carboxyl-terminal deletions of the IL-5-R bc chain. IL-5
activation of TRE-dependent transcription is mediated by amino acids
542–627 of the IL-5-R bc chain. C, Rat-1 cells were transfected as in B
with a large panel of progressive carboxyl-terminal deletions of the
IL-5-R bc chain. It is clear that amino acids 577–581 are involved in
TRE-dependent transcription induced by IL-5. D, Rat-1 cells were
transfected with the TREtataCAT reporter, the wild-type IL-5-R bc
chain and different progressive deletions of the IL-5-R a chain. This
figure shows that amino acids 366–390 of the IL-5-R a chain are
necessary for the IL-5-induced activation of TREtkCAT.
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tagged p54SAPK/JNK was then determined using an anti-
epitope antibody in an immune-complex kinase assay. Fig. 2D
shows that in both cell types, IL-5 significantly enhanced the
activity of the transfected p54SAPK/JNK. Taken together, it
seems likely that the observed activation of TRE-dependent
transcription by IL-5 was caused by phosphorylation of c-Jun
by JNK/SAPK.
To provide further evidence for this model, we tested the
activity of the different bc chain mutants in the transient
p54SAPK/JNK activation assay. Fig. 3A shows that the region
between 542 and 627 is necessary for IL-5-induced enhance-
ment of p54SAPK/JNK kinase activity. Moreover, as we de-
scribed above for the activation of TRE-dependent transcrip-
tion, mutant 581, but not 577, fully supported IL-5-induced
p54SAPK/JNK activation (Fig. 3B). This again supports the
hypothesis that IL-5-induced TRE activation is mediated by
JNK/SAPK.
Activation of DSE-dependent Transcription by IL-5—It was
shown recently that besides c-Jun, JNK/SAPK also phospho-
rylates and activates p62TCF/ELK-1, one of the transcription
factors regulating the activity of the dyad symmetry element
(DSE) in the c-fos promoter (41, 42). Therefore, we set out to
determine whether IL-5 will also activate DSE-dependent tran-
scription in our transient system. A reporter construct contain-
ing three copies of the DSE coupled to tkCAT was transfected
in Rat-1 cells together with the IL-5-R a and bc chains. Inter-
estingly, IL-5 causes a 4-fold increase in DSE-dependent tran-
scription in these cells (Fig. 4). Moreover, as we demonstrated
for TRE and p54SAPK/JNK activation, bc 581 was able to
activate DSEtkCAT activity, whereas bc 577 had lost this
ability (Fig. 4).
ERK2 Is Not Involved in Activation of TRE- or DSE-depend-
ent Transcription by IL-5—Activation of DSE-dependent tran-
scription can also be accomplished by the RAS-ERK2 kinase
pathway (40, 51). Moreover, it was shown recently that tyro-
sine 577 of the bc chain is involved in activation of this pathway
by GM-CSF (28). We, therefore, determined whether activation
of MAP kinase was involved in the observed regulation of TRE-
and DSE-dependent transcription by IL-5. For this purpose, we
used PD098059, a potent and selective inhibitor of the MAP
kinase kinase MEK (43). PD098059 was indeed able to block
ERK2/MAP kinase hyperphosphorylation induced by IL-5 in
Rat-1 cells (Fig. 5A). Moreover, PD098059 completely blocks
IL-5-induced ERK2/MAP kinase activity in Rat-1 cells (Fig.
5B). However, Fig. 6A shows that preincubation with
PD098059 did not alter TRE-dependent CAT activity in IL-5-
treated cells. Moreover, PD098059 pretreatment did also not
influence IL-5-induced DSE activation (Fig. 6B) or IL-5-in-
duced p54SAPK/JNK kinase activity (Fig. 6C). These results
and those described previously strongly suggest that activation
of TRE- and DSE-dependent transcription is mediated by JNK/
SAPK but not by the ERK2/MAP kinase pathway.
To further investigate the role of JNK/SAPK in IL-5 induced
TRE and DSE activation, we used a construct expressing dom-
inant-negative SEK (SEK-AL, made by mutating serine 254 to
alanine and threonine 258 to leucine; Refs. 46 and 47), an
efficient repressor of JNK/SAPK activity. Indeed, when domi-
nant-negative SEK was transfected in Rat-1 cells, IL-5-induced
JNK/SAPK activity was strongly repressed (Fig. 7, right panel).
FIG. 2. IL-5 induces hyperphosphorylation of c-Jun and acti-
vation of JNK/SAPK. A, TF-1 cells were treated with IL-5 (0.5 nM) or
IL-3 (0.5 nM) for different periods of time, after which nuclear extracts
were prepared and assayed for Jun/AP-1 DNA binding activity in a
bandshift assay using the collagenase TRE. Only the Jun/AP-1-DNA
complex is shown. Neither IL-5 nor IL-3 modulate the binding activity
of Jun/AP-1. B, TF-1 cells were labeled with [32P]orthophosphate and
subsequently stimulated with different cytokines for 20 min or with
cycloheximide (CH, 200 mM) for 1 h. Cells were then lyzed, and c-Jun
was immunoprecipitated. In unstimulated cells (con), c-Jun is already
phosphorylated (pJun). However, IL-5 treatment causes a significant
increase in c-Jun phosphorylation (ppJun). As controls, TNFa (1000
units/ml) and cycloheximide cause an even stronger enhancement in
c-Jun phosphorylation. C, TF-1 cells were treated with IL-5 (0.5 nM) for
20 min or with cycloheximide (200 mM) for 60 min. JNK/SAPK kinase
activity was then assayed using an immune-complex kinase assay with
purified GST-Jun protein as a substrate. IL-5 enhances JNK/SAPK
activity about 3-fold, whereas cycloheximide causes a 10-fold increase
in GST-Jun phosphorylation. D, Cos-1 or Rat-1 cells were transfected
with the IL-5-R a and bc chains and an expression vector encoding a
tagged version of p54SAPK/JNK. Cells were treated with IL-5 in the
indicated concentrations for 20 min, after which the kinase activity of
the transfected p54SAPK/JNK was determined. IL-5 treatment leads to
a significant increase in the activity of p54SAPK/JNK in both cell types.
FIG. 3. Activation of p54SAPK/JNK kinase activity in trans-
fected cells is mediated by IL-5-R bc residues 581–577. A, Rat-1
cells were transfected with the tagged p54SAPK/JNK, the IL-5-R a
chain, and a general set of deletion mutants of the IL-5-R bc chain. Cells
were treated with IL-5 (0.5 nM) for 20 min, after which the kinase
activity of the tagged p54SAPK/JNK was determined and quantified. It
is clear that amino acids 542–627 of the bc chain are necessary for the
induction of p54SAPK/JNK activity by IL-5. B, Rat-1 cells were trans-
fected as in A with a more detailed set of IL-5-R bc chain mutants.
Amino acids 577–581 are involved in activation of p54SAPK/JNK by
IL-5.
FIG. 4. Activation of DSE-dependent transcription by IL-5.
Rat-1 cells were transfected with the IL-5-R a chain, a series of IL-5-R
bc chain mutants, and a reporter containing three copies of the DSE
from the human c-fos promoter coupled to tkCAT. Cells were treated
with or without IL-5 (0.5 nM) for 12 h, after which CAT activity was
determined. IL-5 treatment causes a 4-fold increase in DSE-dependent
CAT activity, which is mediated by amino acids 577–581 of the IL-5-R
bc chain.
IL-5 Activates JNK/SAPK2322
Interestingly, dominant-negative SEK also reduces IL-5-in-
duced TRE- and DSE-dependent transcription, suggesting that
TRE and DSE activation by IL-5 are at least partially mediated
by JNK/SAPK.
JAK2 Is Essential for IL-5-induced TRE- and DSE-depend-
ent Transcription—We and others have shown previously that
IL-5 causes a strong and rapid activation of the JAK2 tyrosine
kinase in different IL-5-responsive cell types (17–19). Because
IL-5 is known to induce tyrosine phosphorylation of the bc
chain, a process that might well be mediated by JAK2 (52), we
wanted to determine whether JAK2 activation by IL-5 is in-
volved in the activation of TRE- and DSE-dependent transcrip-
tion. For this purpose, we used two different approaches. (i) We
transfected two different mutations of the bc chain, dI/II and
dII, into Rat-1 cells and tested their activity on TRE- and
DSE-containing reporters. Although both mutants are wild-
type around tyrosine 577, mutant dI/II contains an internal
deletion that removes both box1 and box2 from the full-length
bc receptor, whereas dII is only lacking box2 in the full-length
bc receptor. Deletion of both box1 and box2 completely blocked
IL-5-induced TRE and DSE activation, whereas deletion of only
box2 did not have any effect (Fig. 8). Interestingly, box1, but
not box2, was shown previously to be involved in JAK2 binding
and activation (19, 52). (ii) We used the tyrphostin AG490,
which was shown previously to be an inhibitor of JAK2 (44).
Fig. 8 shows that this inhibitor indeed causes a dose-dependent
decrease in IL-5-induced TRE and DSE activity, although we
failed to completely block these processes. Control experiments
showed that AG490 caused a significant but not complete block
in IL-5-induced JAK2 activation (data not shown). We, there-
fore, conclude that JAK2 is likely to be involved in IL-5-induced
activation of TRE- and DSE-dependent transcription (Fig. 9).
DISCUSSION
IL-5 binding to its receptor results in the activation of mul-
tiple signaling pathways, including the RAS/MAPK pathway
(50), the phosphatidylinositol 39-kinase pathway (51) and the
JAK/STAT pathway (17–19, 27). Here we show that IL-5 acti-
vates TRE- and DSE-dependent transcription via activation of
JNK/SAPK. Moreover, we present evidence that activation of
JAK2 is necessary for this process.
Immediate-early gene induction in response to growth fac-
tors and phorbol esters can be mediated by a DSE/SRE cis-
acting elements present in the promoters of induced genes
(reviewed in Ref. 37). The DSE/SRE binds serum response
FIG. 5. The MEK inhibitor PD098059 blocks IL-5-induced
ERK2/MAP kinase activation in Rat-1 cells. A, a Rat-1 clone stably
expressing the IL-5Ra and b chains was treated with the MEK inhibitor
PD098059 (50 mM), the JAK2 inhibitor AG490 (50 mM), or buffer alone
for 30 min, after which IL-5 (0.5 nM) was added for another 5 min. Cells
(200,000) were then lyzed in SDS sample buffer and analyzed by West-
ern blotting. IL-5 treatment causes a significant phosphorylation (acti-
vation) of ERK2, which is fully inhibited by PD098059 but not by
AG490. B, Rat-1 cells were transfected with the IL-5-R a and bc chains
and an epitope-tagged version of ERK2. Thirty-six h after transfection,
cells were treated with the MEK inhibitor PD098059 (50 mM) or buffer
alone for 20 min, after which IL-5 (0.5 nM) was added for another 5 min.
ERK2 kinase activity was measured using an immune-kinase assay
using MBP as a substrate. IL-5-induced ERK2 kinase activity is com-
pletely blocked by pretreatment with PD098059.
FIG. 6. ERK2/MAP kinase is not involved in TRE, DSE, or
p54SAPK/JNK activation by IL-5. A, Rat-1 cells were transfected
with the IL-5-R a and bc chains and the TREtataCAT reporter con-
struct. Cells were then treated with the MEK inhibitor PD098059 (50
mM) for 1 h, after which IL-5 (0.5 nM) was added for another 12 h.
Activation of MEK and MAP kinase is not necessary for activation of
TRE-dependent CAT activity by IL-5. B, Rat-1 cells were transfected as
in A but instead of the TREtataCAT, the DSEtkCAT construct was used
as reporter. Again, MEK and MAP kinase do not seem to be involved in
IL-5-induced DSE activation. C, Rat-1 cells were transfected with the
IL-5-R a and bc chains and the tagged version of p54SAPK/JNK. Cells
were treated as described in A. p54SAPK/JNK activity was then deter-
mined with an immune-complex kinase assay using GST-Jun as a
substrate. Activation of p54SAPK/JNK by IL-5 occurs independently
from MEK and MAP kinase activation.
FIG. 7. JNK/SAPK is involved in TRE- and DSE-dependent
transcription by IL-5. Rat-1 cells were transfected with the IL-5-R a
and bc chains and the TREtataCAT reporter (left), the DSE reporter
(middle), or the tagged version of p54SAPK/JNK (right) together with a
dominant-negative SEK expression vector (dnSEK; SEK-AL, Refs. 46
and 47) or the insertless expression vector control (con). After 24 h, IL-5
(0.5 nM) was added for another 12 h. CAT activity and p54SAPK/JNK
activity were determined as described above. It is clear that blocking
p54SAPK/JNK activity by dominant-negative SEK also inhibits IL-5
induced TRE- and DSE-dependent transcription.
FIG. 8. JAK2 is likely to be involved in TRE- and DSE-depend-
ent transcription induced by IL-5. Rat-1 cells were transfected with
the IL-5-R a chain, the IL-5-R bc chain (WT), or mutants of bc from
which either box1 and box2 (dI/II) or boxII alone (dII) were deleted. As
reporters, TREtataCAT or DSEtkCAT were used. Some samples were
incubated with the JAK2 inhibitor AG490 for 8 h prior to the addition
of IL-5 (0.5 nM). Twelve h after IL-5 addition, CAT activity was deter-
mined. JAK2 activation seems to be involved in both TRE and DSE
activation, because deletion of the JAK2 binding site of the bc chain
(box1) or blocking JAK2 activity with AG490 inhibits both TRE and
DSE activation by IL-5 at least partially.
IL-5 Activates JNK/SAPK 2323
factor and proteins from the TCF family including Elk-1,
SAP-1, and NET-1/ERP/SAP-2 (reviewed in Ref. 38). Upon
growth factor signaling, Elk-1 is phosphorylated by the ERK
group of MAP kinases, resulting in increased ternary complex
formation as well as activation of the transcriptional activation
domain of Elk-1 (38–40). Because IL-5 efficiently activates
ERK2 (50)(Fig. 5), it is surprising that blocking this process
with PD098059 does not influence IL-5-induced DSE activation
(Fig. 6). At present, we can only speculate on this apparent
contradiction. It is possible that phosphorylation and activa-
tion of Elk-1 by ERK2 is a cell type-specific process that in-
volves components that might not be available in our IL-5-
induced cellular system. However, because there are no
examples of cell type-specific Elk-1 phosphorylation, it seems
more likely that both ERK and JNK/SAPK are capable of
activating Elk-1 in IL-5-stimulated cells. Activation of Elk-1 by
JNK/SAPK is not unprecedented, because it was recently
shown that JNK/SAPK activators, such as UV or IL-1, effi-
ciently activate Elk-1 though phosphorylation on sites identical
to those phosphorylated by ERK2 (41, 42). Blocking either the
ERK or JNK/SAPK pathway, therefore, does not significantly
alter IL-5-induced DSE activity because the other pathway is
redundant. This redundancy was also suggested by Cano et al.
(53), who showed that activation of a single MAPK subtype
(ERK or JNK/SAPK) is sufficient to elicit a complete nuclear
response. Further demonstration of this functional redundancy
awaits the availability of an efficient JNK/SAPK inhibitor.
In agreement with our results, it was shown previously that
box 1 and tyrosine 577 of the bc chain are involved in the
activation of the c-fos promoter by GM-CSF (28, 52). However,
mutation of tyrosine 577 (Y577F) in the context of the full-
length bc chain resulted in only partial inhibition of c-fos in-
duction by GM-CSF. This phenomenon was explained by the
fact that other phosphorylated tyrosines might play a role in
c-fos induction by GM-CSF (28). It was also suggested that the
RAS/ERK cascade was essential for GM-CSF-induced c-fos ex-
pression, because dominant-negative RAS expression effi-
ciently blocks c-fos induction by GM-CSF (28, 54). Our results
with the MEK inhibitor PD098059 (Figs. 5 and 6) suggest that
the ERK2/MAP kinase cascade is not involved in DSE (and
c-fos) induction by IL-5. Although these results seem to be in
contrast, they might be explained by the fact that activated
RAS also stimulates the JNK/SAPK pathway (55, 56), although
TNFa induction of JNK/SAPK occurs in a RAS-independent
manner (56). Because PD098059 efficiently blocks ERK2
activation, but not RAS activation, the result with the dom-
inant-negative RAS might be explained by inhibition of
JNK/SAPK and, therefore, inhibition of GM-CSF-dependent
c-fos expression.
Inhibition of IL-5-induced JAK2 activation by using bc chain
mutants or the tyrphostin AG490 resulted in a decrease in
IL-5-induced TRE and DSE activation (Fig. 8). Therefore,
JAK2 activation seems to play a role in IL-5 signaling apart
from STAT activation. In agreement with our results,
Watanabe et al. (52) showed recently that blocking JAK2 with
dominant-negative JAK2 forms inhibits c-fos promoter activa-
tion by GM-CSF. It is worthwhile to mention that JAK2 was
also shown to be necessary for ERK2 activation by growth
hormone (57). Because the bc chain is phosphorylated on mul-
tiple tyrosine residues after IL-5 stimulation, including tyro-
sine 577 (28), it seems likely that JAK2 is the kinase respon-
sible for this phenomenon. Indeed, dominant-negative JAK2
expression resulted in abrogation of bc phosphorylation after
GM-CSF addition (57). The phosphorylated tyrosine 577 might
well be the binding site for adapter proteins such as Shc, Grb2,
P80, and other proteins responsible for transmitting the IL-5/
GM-CSF-induced signal from the bc chain through the cyto-
plasm (28, 29, 58). Verification of this model awaits the precise
identification of bc residues that are phosphorylated by JAK2
and the characterization of proteins binding to these residues.
Although the cytoplasmic domain of the bc chain of the
IL-5/IL-3/GM-CSF receptors is essential for all previously de-
scribed intracellular signaling events, we have shown that
amino acids 366–390 of the a chain are also necessary for
IL-5-induced TRE and DSE activation (Fig. 1D). This is not
trivial, because a366 is able to form a high affinity binding
receptor with the bc chain (30). We have shown previously that
this region is essential for IL-5-induced STAT3 activation (27).
This region contains conserved proline residues that are also
found in the IL-3-R a, GM-CSF-R a, prolactin receptor and
growth hormone receptor. Site-directed mutagenesis showed
that these prolines are essential for IL-5-induced proliferation
and c-jun and c-fos induction as well as JAK2 activation (30,
31). Recent evidence suggests that the cytoplasmic domain of
the a chain is necessary for the activation of a preformed bc
dimeric complex (59). However, the molecular mechanism re-
sponsible for this process remains to be determined.
Taken together, we describe for the first time that besides
ERK2, IL-5 also activates MAP kinases of the JNK/SAPK fam-
ily. The underlying mechanism as well as the functional con-
sequence of this process for IL-5-induced responses in eosino-
phils are objectives of future study.
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